ImTek MicroCAT II MicroCT Scanner

ImTek MicroCAT II MicroCT 扫描仪

• 批准号: 6877565
• 负责人: JAMEY P WEICHERT
• 金额: $ 38.65万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-15 至 2006-02-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6877565
• 关键词: anatomy; biomedical equipment purchase; cell morphology; computed axial tomography; molecular /cellular imaging; neoplasm /cancer diagnosis; noninvasive diagnosis; structural biology

DESCRIPTION (provided by applicant): There has been a dramatic increase in noninvasive microimaging of small animal tumor models at the University of Wisconsin over the past two years. This interest was mainly stimulated by the purchase of a MicroCAT I (ImTek) microCT scanner capable of 40-micron spatial resolution in live mice. The utility of our microCT scanner is enhanced significantly by the availability of cell-selective CT contrast agents being developed by Dr. Jamey Weichert of the Contrast Agent Development Lab, a joint effort between the Department of Radiology and the University of Wisconsin Comprehensive Cancer Center (UWCCC). To our knowledge, these agents are the only molecular CT contrast agents that are suitable for use with microCT scanners. Accordingly, our laboratory has reported the detection of numerous soft tissue tumors including breast, pancreatic, lung, intestinal, prostate, as well as sub 300-micron liver tumors in live mice. We are now able to "fly through" the lumen of blood vessels less than 150 microns in diameter using our long-acting vascular contrast agent and can also perform virtual colonoscopy in live mice. Collaborative microimaging efforts within the University exploded with the awarding of a P20 Molecular Imaging Center Planning grant, which formalized interactions between imaging scientists and Mouse Models of Human Cancer consortium investigators directed by Dr. William Dove, as well as other cancer biologists. MicroCT demand has overwhelmed our capacity. In addition to creating tremendous campus demand, our advanced microCT molecular imaging efforts have resulted in collaborative requests from extramural academic investigators as well as pharmaceutical companies, and even ImTek. The aim of this proposal is to acquire an ImTek MicroCAT-II microCT scanner. This instrument affords our researchers sub-18 micron spatial resolution, the capability of scanning live rats by virtue of its larger gantry and detector, faster acquisition and reconstruction times, and microPET-compatible beds. A second scanner will permit us to continue development of our innovative cell-selective contrast agents, while continuing to advance novel small animal tumor imaging strategies. As the leader in cell-selective CT contrast agent development, it is our intent to continue development of these unique agents and make them available to other microCT investigators.

描述（由申请人提供）： 在过去的两年中，威斯康星大学的小动物肿瘤模型的非侵入性微型成像急剧增加。这种兴趣主要是通过在活小鼠中购买40微米空间分辨率的微型I（IMTEK）微克扫描仪来刺激这种兴趣。通过造影剂开发实验室的Jamey Weichert博士开发的细胞选择性CT对比剂的可用性，我们的MicroCT扫描仪的实用性得到了显着增强，这是放射学系与威斯康星大学综合癌症中心（UWCCC）之间的共同努力。据我们所知，这些药物是唯一适合与Microct扫描仪一起使用的分子CT对比剂。因此，我们的实验室报告了对活小鼠中乳腺癌，胰腺，肺，肠，前列腺以及300微米肝肿瘤的许多软组织肿瘤的检测。现在，我们能够使用我们的长效血管对比剂“飞过”直径小于150微米的血管腔，还可以在活小鼠中进行虚拟结肠镜检查。大学内的合作微型成像努力爆炸了，授予了P20分子成像中心计划赠款，该计划将成像科学家与威廉·多夫（William Dove）博士指导的人类癌症联盟研究人员以及其他癌症生物学家之间的人类癌症联盟研究人员的模型形式化。 Microct需求使我们的能力不堪重负。除了提出巨大的校园需求外，我们先进的Microct分子成像工作还导致了校外学术研究人员以及制药公司甚至IMTEK的协作要求。该提案的目的是获得IMTEK Microcat-II Microct扫描仪。该仪器为我们的研究人员提供了以下微米的空间分辨率，扫描活大鼠凭借其更大的龙门和检测器的能力，更快的获取和重建时间以及与Micropet兼容的床。第二个扫描仪将使我们能够继续开发创新的细胞选择性对比剂，同时继续推进新型的小动物肿瘤成像策略。作为细胞选择性CT对比剂开发的领导者，我们的目的是继续开发这些独特的代理，并使其他Microct研究人员可以使用它们。